- Home
- Companies
- usa california
- drugs design
Show results for
Refine by
Drugs Design Suppliers In Usa California
17 companies found
based inSan Francisco, CALIFORNIA (USA)
The invenious platform aims to enhance safety, efficacy, sterility, value and convenience. BioQ designs ready-to-use delivery systems for hard to prepare and hard to administer infusible drugs – thereby simplifying the infusion process from ...
based inMonterey, CALIFORNIA (USA)
Vybion has pioneered vectorized Intrabodies, the delivery of functional antibody fragments in the scFv format to cells using Adeno associated virus (AAV). The Company has Orphan Drug Designation from the FDA for INT41 to treat Huntington’s disease a ...
INT41 has received Orphan Drug Designation from the FDA for Huntington’s disease. IND enabling studies for INT41 Gene Therapy for Huntington’s disease are in place following a preIND meeting with the FDA ...
based inOceanside, CALIFORNIA (USA)
Eidogen-Sertanty is dedicated to improving health, medicine, and general well-being. For the last 20-years, Eidogen-Sertanty has helped to expedite the discovery and development of many new, safer medicines through collaborative project team ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
OPC1 is an oligodendrocyte progenitor cell therapy that is currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (SCI). Oligodendrocyte progenitor cells (OPCs) are naturally-occurring precursors to the cells which ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
based inSan Francisco, CALIFORNIA (USA)
Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery. The Atomwise team invented the use of deep learning for structure-based drug design; this technology underpins ...
based inSan Carlos, CALIFORNIA (USA)
Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and ...
One the key chronokine targets identified using Alkahest’s platform is eotaxin. Eotaxin is an immunomodulatory chemokine that is increased in normal aging as well as multiple diseases of aging. It has been implicated in Alzheimer’s ...
based inLancaster, CALIFORNIA (USA)
Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as ...
With the ability to predict over 175 properties, it integrates seamlessly with computational chemistry and medicinal chemistry applications, offering precise predictions on solubility, logP, pKa, and sites of CYP metabolism. Enhanced through ...
based inSan Diego, CALIFORNIA (USA)
Welcome to Molsoft LLC! Molsoft is a leading provider of tools, databases and consulting services in the area of structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and animation, and rational drug ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of ...
based inGeneva, SWITZERLAND
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric ...
Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inBerkeley, CALIFORNIA (USA)
InterX, led by Nobel Prize-winning scientists, is developing tools for pharmaceutical ligand design, material science, and biochemistry. We leverage our proprietary software tools for internal molecule development work, as well as joint ventures. ...
InterX Development Division focuses on bridging the risk gap in Drug Discovery from drug targets to novel candidates. The Development Division applies InterX’s proprietary computer-aided drug ...
based inSacramento, CALIFORNIA (USA)
Ainnocence is a next-generation biotech aiming to create a self-evolving modularized intelligent platform that integrates various advanced computational and wet lab technologies to revolutionize the drug discovery and development process. We ...
Simple : CarbonAI searches over 1.9 billion compounds to create synthesizable drug candidates – based only on target sequence. Precise : CarbonAI accurately identifies the most active and safe compound with a multi-objective optimization ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
![Ibio - Model 100 - Idiopathic Pulmonary Fibrosis [IPF] Therapeutics](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyNTA4Ny9wcm9kdWN0cy84NTMxMzQvMTI1MDg3XzJfMjAyMzAyMTMwNjEwNTM5ODQxNzI5X3Jhdy5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MTQzLCJoZWlnaHQiOjEwMn19fQ== "Ibio - Model 100 - Idiopathic Pulmonary Fibrosis [IPF] Therapeutics")
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, ...
based inSan Diego, CALIFORNIA (USA)
Capricor is Developing Transformative Cell and Exosome-based Therapeutics for the Treatment and Prevention of Diseases. Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and ...
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since ...